GradientHomeSearchIndexFeedback

Back    Back to Vendors

PointofCare.net


Spectral Diagnostics

Decision Point Diagnostics
1.888.35.HEART  (USA)
1.888.4.AMI.AMI (Canada)
416.626.3233 (Worldwide)
info@spectraldiagnostics.com

www.spectraldiagnostics.com/


CORPORATE DESCRIPTION: 

Spectral Diagnostics Inc. remains dedicated to being the leader in the research, development and commercialization of decision point diagnostics.  Our commitment to the development of new and novel rapid tests, such as the patented Cardiac Panel™, reagents and membranes, distinguishes the Company's approach to the diagnosis of cardiac and other serious conditions at the medical decision point.  Spectral is a Canadian publicly traded company incorporated in 1991 with operations in Canada, the United States and Europe.  Spectral's products are available worldwide. 

Each year several million people arrive at hospitals or other acute care settings suffering from chest pain.  Spectral's Cardiac STATus™ tests are designed to assist healthcare professionals in making accurate, timely decisions on the earliest initiation of life saving treatments, to the prevention of unnecessary hospital stays with rapid and effective risk assessment.  Rapidly triaging patients who are undergoing a cardiac event from those with less serious problems can lead to improved patient outcomes while saving money in the process.

The American College of Cardiology and the European Society of Cardiology have changed the clinical and diagnostic definition of myocardial infarction.  Current technology can detect areas of myocardial necrosis under 1 g in weight.  Positive blood tests for cardiac troponin or CK-MB can accurately and reliably label these small infarcts as an MI. Spectral's proprietary technology utilizes a multiple cardiac marker approach. This allows a wide window for early and late chest pain presentations and provides the sensitivity and specificity to accurately rule in and rule out AMI within minutes.

 TopBack to top


Products
The Spectral Cardiac STATus™ tests are simple, hand held cardiac marker panel tests which support the ACC/AHA guidelines and recommendation for diagnosis of MI.   

These clinically proven products quickly and accurately determine elevations of multiple cardiac markers - enabling health care providers to easily assess and diagnose chest pain at the decision point.
 
Providing time critical diagnostic information within minutes!

A fast, easy and convenient diagnostic tool:

The Cardiac STATus™ product line will benefit emergency departments, critical care units, point of care and other healthcare settings.

  • Sample material - whole blood, plasma or serum
  • Results within 15 minutes - positive as early as 3-5 minutes
  • Requires no instrumentation
  • Room temperature stable
  • Simple to use...just add blood
  • Internal control on every test
  • Results are simple to interpret - any presence of a band is indicative of a positive result!

Myoglobin/Troponin 
Cat. No. CS2003

Myoglobin and Troponin I measurements are complementary in the diagnosis of AMI due to the staggered release kinetics of the two proteins after an ischemic cardiac injury.

  • Effectively guides early and appropriate patient management and therapy decisions

  • Myoglobin, a sensitive early marker, often elevates within 2 hours

  • an effective tool to rule-out MI

  • Troponin I, a specific later rising marker reaches upper limit in 4-6 hours

  • proven specific in myocardium

Troponin I
Cat. No. CS1002

This test kit will identify Troponin I in human whole blood, which is the single most critical determination central to the revised definition of acute myocardial infarction (AMI).

  • Specific to myocardium with elevations occurring only in patients with cardiac injury

  • Troponin I has high sensitivity to detect early and minor myocardial injury

  • Elevations can persist for up to 7-10 days, allowing detection in late chest pain presentations

  • Helps identify patients who are cath lab candidates

CK-MB
Cat. No. CS1003

Spectral's Cardiac STATus™ CK-MB test kit is a rapid in vitro diagnostic test kit for the qualitative determination of CK-MB in human whole blood as an aid in the rule-in of AMI.

  • CK-MB, a specific later rising marker reaches upper limit of normal in approximately 6 hours

  • Proven specific in myocardium

 TopBack to top


[ Home | Search | Index | Feedback ]
Last updated:  03/26/2003
Questions or corrections:  Webmaster
© 2000 Medical Automation Systems, Inc. Legal Notice.